Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that it has submitted a New Drug Application (NDA) to China’s National Medical Products Administration (NMPA) for gecacitinib, the company’s proprietary JAK inhibitor, seeking approval for a third indication – the treatment of active ankylosing spondylitis (AS).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Submission Type | New Drug Application (NDA) |
| Product | Gecacitinib (novel JAK inhibitor) |
| Indication | Active ankylosing spondylitis (AS) |
| Submission Date | 14 Oct 2026 |
| Prior Approvals | Intermediate‑to‑high‑risk myelofibrosis; severe alopecia areata in adults |
| Next Steps | NMPA technical review; approval timeline not disclosed |
Drug Profile & Mechanism of Action
- Molecule: Gecacitinib, a novel Janus kinase (JAK) inhibitor independently developed by Zelgen – an orally administered small molecule that modulates JAK‑STAT signaling pathways driving inflammatory and immune responses.
- Intellectual Property: Zelgen holds proprietary intellectual property rights to the product, supporting a differentiated, China‑originated asset.
- Approved Indications (2): The NMPA has previously granted marketing approval for gecacitinib in intermediate‑to‑high‑risk myelofibrosis and severe alopecia areata in adults.
- Reimbursement Status: The myelofibrosis indication was included in the 2025 National Reimbursement Drug List (NRDL), giving the product established payer coverage and commercial infrastructure in China.
- Portfolio Strategy: The AS filing marks the third indication for gecacitinib, extending the molecule from hematologic oncology and dermatology into chronic autoimmune inflammatory disease.
Disease Landscape – Ankylosing Spondylitis
- Disease Profile: AS is a form of arthritis characterized by long‑term inflammation of the axial joints, typically manifesting as inflammation of the sacroiliac joints and entheses along the spine, leading to chronic back pain, stiffness and potential structural damage.
- Unmet Need: As a lifelong condition predominantly affecting younger adults, AS requires sustained anti‑inflammatory therapy; JAK inhibitors have emerged as an important oral alternative to injectable biologics for patients with active disease.
- Clinical Evidence for Gecacitinib in AS: Trial data not disclosed in the announcement.
Market Impact & Outlook
- China AS Market Size: The market for ankylosing spondylitis medications in China reached RMB 17 billion in 2025, growing at a 12.1% CAGR from 2020 to 2025 – signaling sustained expansion of the treatment population and spending.
- Competitive Positioning: If approved, gecacitinib would join an increasingly crowded oral JAK inhibitor class in AS, with Zelgen leveraging its proprietary IP and existing NRDL‑covered commercial presence as strategic advantages.
- Commercial Synergy: The company’s established hematology and dermatology launch experience, plus reimbursement infrastructure from the myelofibrosis NRDL inclusion, could accelerate AS market access negotiations post‑approval.
- Pipeline Value: A successful third indication would materially broaden gecacitinib’s revenue base and reinforce Zelgen’s position among China’s innovative small‑molecule developers.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the NMPA review of gecacitinib for active ankylosing spondylitis, potential approval timelines, reimbursement outcomes and commercial expectations. Actual results may differ materially due to risks including regulatory review requirements, clinical data sufficiency, competitive dynamics and pricing pressures in the Chinese AS market.-Fineline Info & Tech
